GeneDx Holdings Corp. (WGS) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today

On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026. GeneDx then reported Q1 2026 adjusted EPS of -$0.28 -- versus consensus expectations of -$0.01 -- representing an adjusted net loss of $8.2 million in the same quarter management had projected would be profitable.

The stock fell approximately 41% to 49% after Q1 2026 results, as adjusted EPS of $0.28 significantly missed consensus -$0.01 consensus, widening the gap between the numbers investors were given and the results that followed.

If you suffered a loss on your GeneDx Holdings Corp. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296529